ライフサイエンスコーパス: puromycin aminonucleoside

1 sceptibility to glomerular damage induced by puromycin aminonucleoside.

2 d can be induced in rats by the injection of puromycin aminonucleoside.

3 romatic substitution with dimethylamine gave puromycin aminonucleoside [9-(3-amino-3-deoxy-beta-D-rib

4 ycin, cycloheximide, emetine, puromycin, and puromycin aminonucleoside, a negative analog, were evalu

5 Treatment of differentiated podocytes with puromycin aminonucleoside, an agent that causes foot pro

6 with proteinuria and hypoalbuminemia in the puromycin aminonucleoside and adriamycin rat models of n

7 cyte injury was induced in C57BL/6 mice with puromycin aminonucleoside, and the selective A(2A)R agon

8 to glomerular injury, because treatment with puromycin aminonucleoside enhanced proteinuria in TG mic

9 a, along with improved plasma albumin in the puromycin aminonucleoside glomerular disease model.

10 Glomerular proteinuria was induced with puromycin aminonucleoside in rats.

11 Sprague-Dawley rats by an i.v. injection of puromycin aminonucleoside in saline; seven control rats

12 us injection of OX-7 monoclonal antibody and puromycin aminonucleoside in which 10(7) SPIO- and DiI-l

13 docytes, before or after sublethal injury by puromycin aminonucleoside, in the presence or absence of

14 lacking cathepsin L are protected from cell puromycin aminonucleoside-induced cell detachment.

15 sion was underscored by the observation that puromycin aminonucleoside-induced cell migration was slo

16 ry and improved podocyte function in the rat puromycin aminonucleoside-induced glomerular disease mod

17 ne significantly protected podocytes against puromycin aminonucleoside-induced injury (designed to mi

18 n of the actin cytoskeleton that accompanied puromycin aminonucleoside-induced injury in vitro.

19 rintegrin reduced peak proteinuria caused by puromycin aminonucleoside-induced nephropathy.

20 ing the peritoneum permeability of rats with puromycin aminonucleoside-induced nephrotic syndrome.

21 ation of alpha(3) integrin protected against puromycin aminonucleoside-induced podocyte detachment.

22 We found that puromycin aminonucleoside-induced proteinuria in rats wa

23 Rats with puromycin-aminonucleoside-induced nephrotic proteinuria

24 gnificantly increased GEN sprouting, whereas puromycin aminonucleoside-injured podocyte supernatant d

25 Notably, in the puromycin aminonucleoside model, hyperfibrinogenemia and

26 In puromycin aminonucleoside nephrosis (PAN), GIV expressio

27 Here, we show that the induction of puromycin aminonucleoside nephrosis involves podocyte mi

28 Furthermore, the rat puromycin aminonucleoside nephrosis model, previously su

29 syndrome in humans, in animals treated with puromycin aminonucleoside, or in humans or animals with

30 docytes in the passive Heymann nephritis and puromycin aminonucleoside (PA) nephrosis rat models of p

31 d mouse podocytes in culture were exposed to puromycin aminonucleoside (PA) to induce apoptosis.

32 ough wild-type C57Bl/6 mice are resistant to puromycin aminonucleoside (PA)-induced nephrosis (PAN),

33 accumulation and phosphorylation of hsp27 in puromycin aminonucleoside (PAN) -induced experimental NS

34 elevated in podocytes from rats treated with puromycin aminonucleoside (PAN) and from patients with f

35 proteinuria in a rat model of MCD induced by puromycin aminonucleoside (PAN) and in vitro cultured mo

36 We performed comparative studies in a puromycin aminonucleoside (PAN) nephropathy rat model tr

37 the effects of this mutation in response to puromycin aminonucleoside (PAN) nephrosis.

38 , 10, 14, and 21 days after the induction of puromycin aminonucleoside (PAN) nephrosis.

39 ague-Dawley rats by intravenous injection of puromycin aminonucleoside (PAN), whereas control rats re

40 Here, we compared responses to puromycin aminonucleoside (PAN)-induced kidney injury be

41 ) on renal function and structure in chronic puromycin aminonucleoside (PAN)-induced nephropathy in r

42 Puromycin aminonucleoside (PAN)-induced nephrosis is a w

43 mage from a glomerular injury-inducing agent puromycin aminonucleoside (PAN).

44 The inactive agent, puromycin aminonucleoside, produced marked repression of

45 d this interaction is disrupted in GECs from puromycin aminonucleoside-, protamine sulfate-, or siali

46 me and GEC foot process effacement using the puromycin aminonucleoside rat model resulted in signific

47 The peritoneum of puromycin aminonucleoside rats displayed an increase in

48 Stimulation of receptor-operated channels in puromycin aminonucleoside-treated podocytes leads to inc

49 e damage (WT1 heterozygous knockout mice and puromycin aminonucleoside-treated rats).

50 Puromycin aminonucleoside treatment up-regulates catheps

51 Puromycin aminonucleoside was without effect on these pa